Format

Send to

Choose Destination
Muscle Nerve. 2011 May;43(5):694-9. doi: 10.1002/mus.21944. Epub 2011 Apr 1.

Soluble activin receptor type IIB increases forward pulling tension in the mdx mouse.

Author information

1
Department of Physiology, Kirksville College Osteopathic Medicine, AT Still University, Kirksville, Missouri 63501, USA. ccarlson@atsu.edu

Abstract

INTRODUCTION:

In this study we investigated the action of RAP-031, a soluble activin receptor type IIB (ActRIIB) comprised of a form of the ActRIIB extracellular domain linked to a murine Fc, and the NF-κB inhibitor, ursodeoxycholic acid (UDCA), on the whole body strength of mdx mice.

METHODS:

The whole body tension (WBT) method of assessing the forward pulling tension (FPT) exerted by dystrophic (mdx) mice was used.

RESULTS:

RAP-031 produced a 41% increase in body mass and a 42.5% increase in FPT without altering the FPT normalized for body mass (WBT). Coadministration of RAP-031 with UDCA produced increases in FPT that were associated with an increase in WBT.

CONCLUSIONS:

Myostatin inhibition increases muscle mass without altering the fundamental weakness characteristic of dystrophic muscle. Cotreatment with an NF-κB inhibitor potentiates the effects of myostatin inhibition in improving FPT in mdx mice.

PMID:
21462203
PMCID:
PMC3075386
DOI:
10.1002/mus.21944
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center